These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

709 related items for PubMed ID: 25869210

  • 1. JAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY, Chen YB.
    Oncotarget; 2015 Jun 10; 6(16):14329-43. PubMed ID: 25869210
    [Abstract] [Full Text] [Related]

  • 2. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H, Jiang L.
    Oncol Res; 2013 Jun 10; 21(3):137-44. PubMed ID: 24512728
    [Abstract] [Full Text] [Related]

  • 3. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M, Zhao J, Zhang LM, Li H, Yu JP, Ren XB, Wang CL.
    J Cancer Res Clin Oncol; 2012 Dec 10; 138(12):2069-77. PubMed ID: 22821179
    [Abstract] [Full Text] [Related]

  • 4. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T, Li Z, Xu L, Zhang Y, Chen H, Gao Y.
    Acta Biomater; 2018 Aug 10; 76():257-274. PubMed ID: 29960010
    [Abstract] [Full Text] [Related]

  • 5. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC, Proia DA.
    Target Oncol; 2015 Jun 10; 10(2):235-45. PubMed ID: 25077897
    [Abstract] [Full Text] [Related]

  • 6. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]

  • 7. Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
    Ito K, Semba T, Uenaka T, Wakabayashi T, Asada M, Funahashi Y.
    Cancer Sci; 2014 Aug 26; 105(8):1023-31. PubMed ID: 24841832
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth.
    Xu L, Meng X, Xu N, Fu W, Tan H, Zhang L, Zhou Q, Qian J, Tu S, Li X, Lao Y, Xu H.
    Cell Death Dis; 2018 Feb 15; 9(3):262. PubMed ID: 29449529
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
    Tong X, Tanino R, Sun R, Tsubata Y, Okimoto T, Takechi M, Isobe T.
    Respir Res; 2019 Dec 02; 20(1):270. PubMed ID: 31791326
    [Abstract] [Full Text] [Related]

  • 13. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W, Chen Y, Zhu KY, Deng H, Wu T, Wang J.
    Biol Pharm Bull; 2017 Aug 01; 40(8):1306-1313. PubMed ID: 28515374
    [Abstract] [Full Text] [Related]

  • 14. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS, Raffeld M, Moon YW, Xi L, Bianco C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, Subramaniam D, Mok T, Rosell R, Luo J, Salomon DS, Wang Y, Giaccone G.
    J Clin Invest; 2014 Jul 01; 124(7):3003-15. PubMed ID: 24911146
    [Abstract] [Full Text] [Related]

  • 15. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH, Shu Y, Chen P, Wu JN, Zhu LH, Yuan RX, Long WG, Zhu YM, Li J.
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec 01; 1864(12):3786-3798. PubMed ID: 30315932
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.
    Mol Cancer Ther; 2012 Oct 01; 11(10):2149-57. PubMed ID: 22844075
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
    Yu W, Lu W, Chen G, Cheng F, Su H, Chen Y, Liu M, Pang X.
    Br J Pharmacol; 2017 Oct 01; 174(20):3608-3622. PubMed ID: 28749535
    [Abstract] [Full Text] [Related]

  • 20. Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling.
    Zhou X, Liu B, Ning Q, Xia Z, Zhong R, Zhang L, Wu L.
    Oncol Rep; 2021 Jan 01; 45(1):217-229. PubMed ID: 33200228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.